Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.
Author
Naveen, RNikiphorou, Elena
Joshi, Mrudula
Sen, Parikshit
Lindblom, Julius
Agarwal, Vishwesh
Lilleker, James B
Tan, Ai Lyn
Salim, Babur
Ziade, Nelly
Velikova, Tsvetelina
Gracia-Ramos, Abraham Edgar
Kuwana, Masataka
Day, Jessica
Makol, Ashima
Distler, Oliver
Chinoy, Hector
Traboco, Lisa S
Wibowo, Suryo Anggoro Kusumo
Tehozol, Erick Adrian Zamora
Serrano, Jorge Rojas
García-De La Torre, Ignacio
Aggarwal, Rohit
Gupta, Latika
Agarwal, Vikas
Parodis, Ioannis
Affiliation
Sandwell and West Birmingham NHS Trust; Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow; King's College London; University of MelbournePublication date
2023-07-05Subject
Rheumatology
Metadata
Show full item recordAbstract
Objective: To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). Methods: Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March-December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. Results: Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). Conclusion: While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE.Citation
Naveen R, Nikiphorou E, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, Tan AL, Salim B, Ziade N, Velikova T, Gracia-Ramos AE, Kuwana M, Day J, Makol A, Distler O, Chinoy H, Traboco LS, Wibowo SAK, Tehozol EAZ, Serrano JR, García-De La Torre I; COVAD Study Group; Aggarwal R, Gupta L, Agarwal V, Parodis I. Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. Rheumatology (Oxford). 2023 Jul 5;62(7):2453-2463. doi: 10.1093/rheumatology/keac661.Type
ArticlePMID
36413073Journal
RheumatologyPublisher
Oxford University Pressae974a485f413a2113503eed53cd6c53
10.1093/rheumatology/keac661